International Edition
Latest News
Health

Weill Cornell Team Develops First-in-Class TNKS2 Inhibitor for WNT Pathway

Researchers at Weill Cornell Medicine have developed a first-in-class inhibitor that selectively targets the TNKS2 enzyme, potentially overcoming a long-standing hurdle in cancer drug development. By focusing on TNKS2 alone, the team aims to suppress the WNT signaling…

Drug Discovery News Logo

Researchers at Weill Cornell Medicine have developed a first-in-class inhibitor that selectively targets the TNKS2 enzyme, potentially overcoming a long-standing hurdle in cancer drug development.

By focusing on TNKS2 alone, the team aims to suppress the WNT signaling pathway—a major driver of tumor growth—without causing the severe gastrointestinal toxicity that previously hindered dual inhibitors.

The WNT signaling pathway is essential for maintaining homeostasis in healthy tissues, which has historically made it a dangerous target for therapy. Earlier attempts to inhibit the WNT pathway by targeting both TNKS1 and TNKS2 enzymes damaged healthy cells in preclinical models.

“When we started using them in cancer cell lines we noticed something unexpected: In some cases, suppressing TNKS2 alone was sufficient to suppress WNT,” Lukas Dow told Drug Discovery News.

Exploiting Cancer Cell Vulnerabilities

The new research, published in Nature Chemical Biology, reveals that certain cancer cells possess a natural dependency on TNKS2 due to the loss of the TNKS1 gene. This deletion often occurs on the short arm of chromosome 8, a genetic change frequently observed in colorectal, breast, lung, liver, prostate, and ovarian cancers.

Because healthy cells typically express both TNKS1 and TNKS2, they remain unaffected by a TNKS2-selective inhibitor. This provides a therapeutic window, allowing the drug to shut down WNT hyperactivation in tumors while sparing normal tissue.

Designing the TDI-012804 Compound

Creating a selective inhibitor proved difficult because the active sites of TNKS1 and TNKS2 are nearly identical. Dow’s team overcame this by identifying a flexible loop in the TNKS2 enzyme that functions differently than its counterpart in TNKS1.

“The key was a flexible loop in TNKS2 that behaves differently from the corresponding loop in TNKS1. Designing small molecules that exploit the conformational flexibility of the TNKS2 loop, ultimately led to our lead compound, TDI-012804,” Dow told Drug Discovery News.

Future Clinical Development

TDI-012804 is an advance, but the current compound is not yet ready for in vivo testing. The research team plans to refine the drug’s properties to improve its efficacy and safety profile before considering human clinical trials.

“The current lead compound is not optimized for in vivo testing, so clinical use is a long way in the future and would depend on successful development of modified compounds,” Dow said.

Challenges in Targeting the WNT Pathway and 8p Deletions

Why has the WNT pathway been difficult to treat?
The WNT pathway is critical for both tumor growth and the maintenance of healthy tissues. Targeting it generally causes systemic toxicity because the drugs cannot distinguish between cancerous and healthy cells.

How common are the 8p chromosome deletions?
These deletions are relatively common in several cancer types, including colorectal, breast, lung, liver, prostate, and ovarian cancers. This genetic loss creates the specific vulnerability that the new TNKS2-selective inhibitor exploits.

What is the next step for this therapy?
The research team is focused on optimizing the drug-like properties of their lead compound, TDI-012804. Further development is required before the therapy can be tested in clinical trials.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”